https://orcid.org/0000-0003-2732-8180
References
- Bodor N, Kaminski JJ, Selk S. Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials. J Med Chem. 1980;23:469–474.
- Janik P, Kosticova M, Pecenak JP, et al. Categorization of psychoactive substances into “hard drugs” and “soft drugs”: a critical review of terminology used in current scientific literature. Am J Drug Alcohol Abuse. 2017;43(6):636–646.
- Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev. 2000;20:58–101.
- Bodor N, Buchwald P. Retrometabolic drug design and targeting. 1st ed. Hoboken, NJ: Wiley; 2012 October 12.
- Stepan AF, Walker DP, Bauman J, et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol. 2011;24(9):1345–1410.
- Laizure SC, Herring V, Hu Z, et al. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy. 2013;33(2):210–222.
- Di L. The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr Drug Metab. 2019;20(2):91–102.
- Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5(12):993–996.
- Rautio J, Meanwell NA, Di L, et al. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov. 2018;17(8):559–587.
- Lee HJ, Cooperwood JS, You Z, et al. Prodrug and antedrug: two diametrical approaches in designing safer drugs. Arch Pharm Res. 2002;25:111–136.
- Aprile S, Serafini M, Pirali T. Soft drugs for dermatological applications: recent trends. Drug Discov Today. 2019;24(12):2234–2246.
- Buchwald P, Bodor N. Recent advances in the design and development of soft drugs. Pharmazie. 2014;69(6):403–413.
- Scannell JW, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):191–200.
- Egan TD. Is anesthesiology going soft? Trends in fragile pharmacology. Anesthesiology. 2009;111(2):229–230.
- Johnson KB. New horizons in sedative hypnotic drug development: fast, clean, and soft. Anesth Analg. 2012;115(2):220–222.
- Bodor N, Buchwald P. Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des. 2006;12(25):3241–3260.
- Buchwald P. Computer-aided retrometabolic drug design: soft drugs. Expert Opin Drug Discov. 2007;2(7):923–933.
- Samir A, Bodor N, Imai T. Identification of esterase involved in the metabolism of two corticosteroid soft drugs. Biochem Pharmacol. 2017;127:82–89.